These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Pachner AR; Cadavid D; Wolansky L; Skurnick J Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576 [TBL] [Abstract][Full Text] [Related]
27. BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. Gandhi KS; McKay FC; Schibeci SD; Arthur JW; Heard RN; Stewart GJ; Booth DR J Interferon Cytokine Res; 2008 Sep; 28(9):529-39. PubMed ID: 18715196 [TBL] [Abstract][Full Text] [Related]
28. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090 [TBL] [Abstract][Full Text] [Related]
29. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K; Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603 [TBL] [Abstract][Full Text] [Related]
30. Antibodies against interferon-beta in multiple sclerosis. Aarskog NK; Marøy T; Myhr KM; Vedeler CA J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718 [TBL] [Abstract][Full Text] [Related]
31. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. Vallittu AM; Erälinna JP; Ilonen J; Salmi AA; Waris M Acta Neurol Scand; 2008 Jul; 118(1):12-7. PubMed ID: 18081914 [TBL] [Abstract][Full Text] [Related]
32. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. McKay F; Schibeci S; Heard R; Stewart G; Booth D J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664 [TBL] [Abstract][Full Text] [Related]
33. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. Cludts I; Meager A; Thorpe R; Wadhwa M J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137 [TBL] [Abstract][Full Text] [Related]
34. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447 [TBL] [Abstract][Full Text] [Related]
35. Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis. Govindappa K; Sathish J; Park K; Kirkham J; Pirmohamed M Eur J Clin Pharmacol; 2015 Nov; 71(11):1287-98. PubMed ID: 26268445 [TBL] [Abstract][Full Text] [Related]
36. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772 [TBL] [Abstract][Full Text] [Related]
37. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Farrell RA; Giovannoni G Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434 [TBL] [Abstract][Full Text] [Related]
38. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Namaka M; Pollitt-Smith M; Gupta A; Klowak M; Vasconcelos M; Turcotte D; Gong Y; Melanson M Curr Med Res Opin; 2006 Feb; 22(2):223-39. PubMed ID: 16466595 [TBL] [Abstract][Full Text] [Related]
39. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Hesse D; Sørensen PS Eur J Neurol; 2007 Aug; 14(8):850-9. PubMed ID: 17662004 [TBL] [Abstract][Full Text] [Related]
40. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Sørensen PS; Deisenhammer F; Duda P; Hohlfeld R; Myhr KM; Palace J; Polman C; Pozzilli C; Ross C; Eur J Neurol; 2005 Nov; 12(11):817-27. PubMed ID: 16241970 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]